$VERA insider trading
Over the last 12 months, Vera Therapeutics insiders reported 1 buy totaling $250K and 16 sales totaling $7.6M across SEC Form 4 filings. 41% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $250K 1 event
- Sold · 12m
- $7.6M 16 events
- Events · 12m
- 17 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 41% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fordyce MarshallPRESIDENT AND CEO · O·D | ▼ Sale | 18,500 | $35.12 | $650K | -7.3% | plan |
| Jul 7, 2026 | Fordyce MarshallPRESIDENT AND CEO · O·D | ▼ Sale | 46,250 | $42.3 | $2.0M | -23.3% | plan · 4 tranches |
| Jun 23, 2026 | Fordyce MarshallPRESIDENT AND CEO · O·D | ▼ Sale | 18,500 | $37.93 | $702K | -8.5% | plan · 2 tranches |
| Apr 14, 2026 | Fordyce MarshallPRESIDENT AND CEO · O·D | ▼ Sale | 22,951 | $44.05 | $1.0M | -8.9% | plan · 3 tranches |
| Feb 23, 2026 | Skelton Laurence MatthewChief Commercial Officer · O | ▼ Sale | 1,582 | $41.98 | $66K | -2.4% | — |
| Feb 23, 2026 | Brenner RobertChief Medical Officer · O | ▼ Sale | 2,151 | $41.98 | $90K | -4.1% | — |
| Feb 23, 2026 | Grant SeanCHIEF FINANCIAL OFFICER · O | ▼ Sale | 4,949 | $41.98 | $208K | -4.2% | — |
| Feb 23, 2026 | Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR · O | ▼ Sale | 3,117 | $41.98 | $131K | -4.6% | — |
| Feb 23, 2026 | Fordyce MarshallPRESIDENT AND CEO · O·D | ▼ Sale | 16,925 | $41.98 | $711K | -6.2% | — |
| Feb 23, 2026 | Turner William D.Chief Regulatory Officer · O | ▼ Sale | 2,187 | $41.98 | $92K | -4.6% | — |
| Feb 23, 2026 | JOHNSON DAVID LEEChief Operating Officer · O | ▼ Sale | 2,579 | $41.98 | $108K | -5.3% | — |
| Dec 15, 2025 | Turner William D.Chief Regulatory Officer · O | ▼ Sale | 10,000 | $50.08 | $501K | -30.8% | plan |
| Dec 11, 2025 | ENRIGHT PATRICK GD | ▲ Buy | 5,882 | $42.5 | $250K | — | — |
| Dec 8, 2025 | Turner William D.Chief Regulatory Officer · O | ▼ Sale | 10,000 | $45.31 | $453K | -30.8% | plan |
| Dec 3, 2025 | Turner William D.Chief Regulatory Officer · O | ▼ Sale | 10,000 | $40 | $400K | -30.8% | plan |
| Nov 21, 2025 | Carter Jason SChief Legal Officer · O | ▼ Sale | 3,864 | $27.82 | $107K | -7.3% | — |
| Nov 11, 2025 | Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR · O | ▼ Sale | 15,000 | $29.06 | $436K | -23.9% | — |
Every $VERA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Vera Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $VERA feed.